12.05.2017 • NewsagmDede WillamsLinde

Linde Leaders Face Criticism at AGM

(c) Linde Group
(c) Linde Group

At Linde’s annual general meeting in Munich on May 10, supervisory board chairman, Wolfgang Reitzle and interim CEO, Aldo Belloni, faced hefty criticism from shareholders’ representatives over the plan to merge with US rival Praxair, adding to the discontent already voiced by employee representatives.

Both groupings fear that the combination with the US player would diminish the standing the traditional German gases and engineering group enjoys. Employees also fear a massive loss of jobs, as Praxair, despite a leaner workforce reportedly produces higher profit margins.

All calls for a vote to block approval of the transaction dissipated, however. The meeting endorsed Reitzle with an acceptance rate of 94.47% and Belloni with 96.3%. Belloni said he hopes to finally clinch the deal with Praxair by the end of June. While it has been known for some time that the US company’s Steve Angel will head the merged gases giant, the current Linde CEO appeared to unofficially confirm speculation that the holding company will be based in Ireland with a tax domicile in the UK.

The Linde workforce has been critical of locating the holding outside Germany, thus weakening labor’s co-determination rights. But at the same time, Belloni pointed out that under the agreement Linde’s 8,000 German employees will be protected from compulsory redundancies until the end of 2021. He also rejected calls for a vote on the merger plans, saying that all Linde shareholders have the right to decide whether to tender their shares.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.